Verizon Extends Cloud Data Management Services to Pharmaceutical Sector
New services manage clinical or drug manufacturing data in the Verizon cloud or from data centers.
Verizon has added two new healthcare-industry solutions designed to help companies keep up with increasing regulatory requirements in the pharmaceutical sector. GxP (Good x Practices) Services will allow companies to manage sensitive clinical and drug-manufacturing data in the Verizon cloud or from select data centers. Verizon will also provide its complementary cloud and data-center service options in a new partnership with rfXcel, which provides a serialization solution that helps companies track and trace pharmaceuticals from manufacturing to distribution.
“Companies within the sector are struggling today to meet growing regulatory requirements,” said Rich Black, vice-president of Verizon’s healthcare practice. “We have found that our IT infrastructure, which leverages our cloud, security, and technical expertise, can enable them to address this burden.”
Verizon’s GxP services include colocation, managed hosting, and enterprise cloud solutions in three of the company’s global data centers, as well as professional services to size or scope the architecture and enable deployment. GxP services come with a baseline ISO 27001 certification. The services are managed under Verizon’s Quality Management Program to deliver qualified infrastructure with appropriate sign-offs on standard operating procedures and to ensure proper training, policies, and document/record control.
A cloud-based, track-and-trace software application is available to clients through rfXcel. This solution is a complete end-to-end service with compliance reporting that uses radio frequency identification (RFID) and a 2D barcode that can be integrated into current enterprise resource planning systems. The rfXcel solution offers serialization, traceability, alerts and notification, error detection and correction, and inventory management capabilities as well as an easy-to-use Web portal.
Source: Verizon Enterprise Solutions
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
